Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone.

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode… Read More ...

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3% ...

A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants ...

WHX to take place from 25–28 January 2027 across Dubai Exhibition Centre, Expo City and Dubai World Trade Centre By ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Chief Market Strategist at SlateStone Wealth, Llc Kenny Polcari joins Stuart Varney to discuss Bitcoin’s rally, Moderna’s ...

Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering ...

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a ...

A Seattle biotech built on University of Washington research has won a $245 million patent judgment against Guardant Health ...

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say Record-breaking cross-border deals helped make some formerly loss-making Chinese ...

Gaps are information. They are the place on the chart where you can see buyers and sellers jumping ahead to a fast repricing, ...